Walmart Partners With Novo Nordisk To Launch US Private-Label Insulin

Company Launches Insulin Aspart And FlexPens As Interchangeable Biosimilars Loom

 
• By Akriti Seth
  
Generate a summary of this article
Listen to this article
Beta

Walmart, the famous American multinational retailer, has launched what it is billing as the “first and only” private brand analog insulin, under the company’s brand ReliOn, in partnership with Novo Nordisk. The firm is offering ReliOn NovoLog (insulin aspart) vials and FlexPen in its pharmacies immediately. 

Walmart
Walmart says it aims to increase access and affordability through its private brand analog insulin launch • Source: Alamy

Walmart has recently announced the launch of the “first and only” private brand analog insulin, under the company’s brand ReliOn, in partnership with Novo Nordisk. The firm is offering NovoLog (insulin aspart) vials priced at $72.88 and FlexPenpriced at $85.88, in a move that the retailer says is expected to “revolutionize the access and affordability to diabetes care by offering customers significant price savings without compromising quality.”

Commenting on Walmart’s new launch, Cheryl Pegus, executive vice president of Walmart health & wellness said, “With ReliOn NovoLog insulin,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C7

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C6

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

US Biosimilars

An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.

Amneal Kicks Off China Business With First Approval

Amneal has marked its entry into China after receiving its first product approval in the market. Meanwhile, the firm has also outlined US approvals for two generics currently suffering from shortages.

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.